NASDAQ:AXDX - Accelerate Diagnostics Stock Price, Forecast & News

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics Inc (NASDAQ:AXDX) issued its quarterly earnings results on Thursday, November, 7th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.01. The medical research company had revenue of $2.27 million for the quarter, compared to analyst estimates of $3.15 million. Accelerate Diagnostics had a negative return on equity of 249.46% and a negative net margin of 1,116.69%. View Accelerate Diagnostics' Earnings History.

Accelerate Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Accelerate Diagnostics.

Accelerate Diagnostics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Accelerate Diagnostics updated its FY 2020 After-Hours earnings guidance on Wednesday, January, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $16-18 million, compared to the consensus revenue estimate of $27.93 million.

4 brokerages have issued 1-year price targets for Accelerate Diagnostics' stock. Their forecasts range from $16.00 to $20.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $18.33 in the next year. This suggests a possible upside of 13.7% from the stock's current price. View Analyst Price Targets for Accelerate Diagnostics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics.

Press coverage about AXDX stock has been trending very positive recently, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of 3.1 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Accelerate Diagnostics.

Some companies that are related to Accelerate Diagnostics include Horiba (HRIBF), Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Arrayit (ARYC), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), BIOLASE (BIOL), Gilead Sciences (GILD), Alibaba Group (BABA), ABIOMED (ABMD), AbbVie (ABBV) and AT&T (T).

Accelerate Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional investors include Credit Suisse AG (5.68%), AXA (3.74%), Chicago Capital LLC (2.40%), ArrowMark Colorado Holdings LLC (2.04%), Cannell Peter B & Co. Inc. (2.00%) and Griffin Asset Management Inc. (1.82%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Credit Suisse AG, Stifel Financial Corp, Barclays PLC, Cannell Peter B & Co. Inc., Trellus Management Company LLC, Bank of America Corp DE and New York State Common Retirement Fund. View Insider Buying and Selling for Accelerate Diagnostics.

AXDX stock was acquired by a variety of institutional investors in the last quarter, including Chicago Capital LLC, AXA, Griffin Asset Management Inc., UBS Group AG, ArrowMark Colorado Holdings LLC, Baird Financial Group Inc., California Public Employees Retirement System and Man Group plc. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXDX stock can currently be purchased for approximately $16.13.

Accelerate Diagnostics has a market capitalization of $881.50 million and generates $5.67 million in revenue each year. The medical research company earns $-88,330,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.View Additional Information About Accelerate Diagnostics.

The official website for Accelerate Diagnostics is http://acceleratediagnostics.com/.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]